Jazz Pharmaceuticals plc(JAZZ) Stock Research - Grey Stern Research

Jazz Pharmaceuticals plc (JAZZ) Stock Analysis

$122.39 (0.61%)

JAZZ Financial Performance


Use the table below to view Jazz Pharmaceuticals plc's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $121.64 -
52 Week Low $99.06 -
52 Week High $134.17 -
Market Cap $7.4 Billion 12/23
Gross Margin 100% 1/23
Profit Margin 20% 4/23
EBITDA margin 25% 4/23
Q3 - 2024 Revenue $1.1 Billion 3/23
Q3 - 2024 Earnings $215.1 Million 3/23
Q3 - 2024 Free Cash Flow $412.7 Million 2/23
Trailing 4 Quarters Revenue $4.0 Billion 3/23
Trailing 4 Quarters Earnings $463.2 Million 5/23
Quarterly Earnings Growth 46% 8/23
Annual Earnings Growth 1% 12/23
Quarterly Revenue Growth 9% 14/23
Annual Revenue Growth 4% 15/23
Cash On Hand $2.2 Billion 2/23
Short Term Debt $31.0 Million 5/23
Long Term Debt $6.2 Billion 2/23

Jazz Pharmaceuticals plc Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Jazz Pharmaceuticals plc's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 15.88 4/23
PS 1.84 18/23
PB 1.76 20/23
PC 3.32 21/23
Liabilities to Equity 1.94 6/23
ROA 0.04 7/23
ROE 0.11 7/23
Current Ratio 1.52 17/23
Quick Ratio 0.27 23/23
Long Term Debt to Equity 1.47 4/23
Debt to Equity 1.48 3/23
Burn Rate 57.21 1/23
Cash to Cap 0.30 3/23
CCR 1.92 5/23
EV to EBITDA 43.50 5/23
EV to Revenue 2.83 18/23

Company Details

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

CEO: Mr. Bruce Cozadd

Website: https://www.jazzpharma.com

Address: Fifth Fl, Waterloo Exchange, Waterloo Road DUBLIN, DUBLIN

Exchange: NASDAQ Global Select

Industry: Biotechnology

Jazz Pharmaceuticals plc Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Jazz Pharmaceuticals plc. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $32.5 Billion
BioMarin Pharmaceutical Inc. BMRN $12.0 Billion
Exelixis, Inc. EXEL $10.1 Billion
Halozyme Therapeutics, Inc. HALO $6.2 Billion
Incyte Corporation INCY $13.9 Billion
Denali Therapeutics Inc. DNLI $3.4 Billion
Seagen Inc. SGEN $43.2 Billion
Ultragenyx Pharmaceutical Inc. RARE $4.3 Billion
United Therapeutics Corporation UTHR $16.5 Billion
Protagonist Therapeutics, Inc. PTGX $2.5 Billion
Blueprint Medicines Corporation BPMC $6.1 Billion
Bio-Techne Corporation TECH $11.9 Billion
argenx SE ARGX $36.6 Billion
Apellis Pharmaceuticals, Inc. APLS $4.3 Billion
Ascendis Pharma A/S ASND $7.8 Billion
Liquidia Corporation LQDA $953.0 Million
Larimar Therapeutics, Inc. LRMR $387.3 Million
Legend Biotech Corporation LEGN $8.0 Billion
Vaxcyte, Inc. PCVX $11.3 Billion
Inhibrx, Inc. INBX $217.1 Million
Viridian Therapeutics, Inc. VRDN $1.6 Billion
DICE Therapeutics, Inc. DICE $2.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
JAZZ Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 1.1 Billion $215.1 Million
Q2 2024 $ 1.0 Billion $168.6 Million
Q1 2024 $ 902.0 Million -$14.6 Million
Q4 2023 $ 1.0 Billion $94.2 Million
Q3 2023 $ 972.1 Million $146.8 Million
Q2 2023 $ 957.3 Million $104.4 Million
Q1 2023 $ 892.8 Million $69.4 Million
Q4 2022 $ 972.1 Million -$240.0 Million

View All

JAZZ Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $2.2 Billion $12.3 Billion $6.2 Billion $4.2 Billion
Q2 2024 $1.3 Billion $11.4 Billion $5.8 Billion $3.8 Billion
Q1 2024 $1.2 Billion $11.3 Billion $5.8 Billion $3.7 Billion
Q4 2023 $1.5 Billion $11.4 Billion $5.8 Billion $3.7 Billion
Q3 2023 $1.3 Billion $11.2 Billion $5.8 Billion $3.5 Billion
Q2 2023 $1.3 Billion $11.3 Billion $5.8 Billion $3.5 Billion
Q1 2023 $1.2 Billion $11.0 Billion $5.8 Billion $3.3 Billion
Q4 2022 $881.5 Million $10.8 Billion $5.8 Billion $3.1 Billion

View All

JAZZ Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $412.7 Million $14.0 Million $862.3 Million
Q2 2024 $324.3 Million -$7.1 Million $62.4 Million
Q1 2024 $260.3 Million -$6.9 Million $27.1 Million
Q4 2023 $94.2 Million $0 $94.2 Million
Q3 2023 $302.9 Million -$4.3 Million $53.4 Million
Q2 2023 $291.0 Million -$5.7 Million $114.4 Million
Q1 2023 $315.9 Million -$4.8 Million $286.4 Million
Q4 2022 -$42.4 Million -$384.4 Million $42.1 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions